Search

everythinglearnresearchcommunity

for

Search:↓

JAM-A modification speeds up skin wound healing by boosting fibroblast growth.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Surgical debridement and targeted therapies can effectively heal chronic wounds in KID syndrome.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

More research is needed to understand and manage rheumatoid arthritis better.

The method successfully visualizes iodine in biological tissues.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

Jieduquyuziyin prescription helps treat SLE with atherosclerosis by improving cholesterol removal and reducing inflammation.

Ajwain seed extract improved skin healing and hair growth in a mouse skin irritation model.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Always consider xanthomatous hypophysitis before deciding on pituitary surgery.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.

P2X₃-IR fibers are widespread in rat skin and likely help detect pain.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

The L412F variant of TLR3 is linked to skin infections, more viral infections, and autoimmune issues.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

Abrocitinib may effectively treat Lichen Planopilaris.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Activating TLR3 boosts autophagy gene expression in skin cells.

Ruxolitinib can help regrow hair in severe alopecia areata.

Itch is a common symptom in patients with chronic venous insufficiency, often worsening with standing or sitting and occurring mostly in the evening or at night.